$BPMC at ASH: establishing itself as the sole landlord of Systemic Mastocytosis (SM):
• Avapritinib (AYVAKIT) +
• Elenestinib

Market cheering it +8% now

Competitor $COGT ouch... down >50%

$BPMC results published yesterday:
• AYVAKIT (avapritinib) printed $71m in Q4 (beat)
• AYVAKIT forecast $360-390m in 2024
• Largest (only?) landlord for SM (Systemic Mastocytosis) ✅
• Market clearly likes the results: +14% y'day +3% now in a down tape❗️

$BPMC is running towards $100 again, I like the prioritization of the company. Elenestinib is the most promising asset behind avapritinib. #Ayvakit sales ramping up. Several opportunities in the future. Oncology on top. $COGT $DCPH $RIGL

May PDUFA Update!...

$BPMC FDA approved AYVAKIT® (avapritinib) yesterday to treat ISM!🎉

$IBRX PDUFA was for today for Anktiva to treat bladder cancer, but received CRL on 5/11 due to deficiencies in the company's application.

$LXRX PDUFA is for 5/27 for Sotagliflozin to treat

Presenting on adolescent patient with KIT mutated CBF SM-AML) treated with Avapritinib and Decitabine. Innovative approach with emphasis on the importance of specialized testing such as NGS and flow sorting. #ASPHO2024 MD Anderson Cancer Center American Society of Pediatric Hematology/Oncology #MedEd

$BPMC 5K systemic mastocytosis (SM) patients in Italy alone

An international congress of experts and patients in Naples held an event: “Drive The Change-Avapritinib: driving the change to build the future of systemic mastocytosis”

facebook.com/PianetaSalute/…

$BPMC Avapritinib / Ayvakit in Japan soon?

'Japan to scrap rule requiring testing of new drugs on Japanese'
November 13, 2023
asia.nikkei.com/Business/Pharm…

#ASCO23 #sarcoma

Approvals of TKIs for GIST!

Unfortunately, in Brazil, no changes since 2013.

We must press for global access to newer TKIs including ripretinib and avapritinib.

Mast cell disease treatments are few, hard to access & difficult to get covered - Mariana castells presents promising results from therapeutic trials with new biologic avapritinib #AAAI23 #immunology

$BPMC Recent 11/16 discussion of avapritinib for indolent systemic mastocytosis

Comments on avapritinib's iSM registrational trial begin at the 36:55 mark
youtu.be/M3RKYTcHSwM?t=…

$BPMC As far as I know, Ayvakit (avapritinib) rights to Australia, Japan and Canada, not to mention global elenestinib rights, are still available

There's an influencer in Australia (mum_with_mastocytosis) documenting her debilitating journey with iSM

x.com/nolastevedore/…

Happening now at #AACR23 is our MD PhD student Kallen Schwark talking about avapritinib treatment effectiveness in H3K27M tumors w/ high PDGFRA expression

$BPMC Blueprint Medicines 'Case Series Confirms Rapid and Profound Response to Avapritinib in AdvSM'

November 16, 2023

Nice comment on the expectations and effectiveness for avapritinib / Ayvakit

rarediseaseadvisor.com/news/sm-news-b…

Avapritinib ha obtenido (¡al fin!) la aprobación en España para pacientes con #GIST con la mutación #PDGFRA D842V

👉El estudio NAVIGATOR demostró una actividad sin precedentes en estos pacientes para los que no existía ningún tratamiento efectivo

🔗thelancet.com/journals/lanon…

$BPMC
🇺🇸
Blueprint Medicines

AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

ir.blueprintmedicines.com/news-releases/…

cc: $COGT

Experience with avapritinib prior to allo-HCF for SM-AHN — 3 illustrative cases! Much more to learn in the space for sure #mastocytosis #mpnsm #LondonMPNsm

ICYMI: The webinar that we hosted on August 24, 2023 about the findings of the PIONEER trial of Avapritinib. You can now find it posted in our webinar library! buff.ly/3Z8pAGe

$BPMC
🇺🇸
Blueprint Medicines

AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis

ir.blueprintmedicines.com/news-releases/…

In case you missed the BIG NEWS last week, the FDA has approved AYVAKIT®(avapritinib) for the treatement of Indolent Systemic Mastocytosis. Our Board Chair, Judi Emmel, was quoted in Blueprint Medicines' press release!
buff.ly/427niXJ

📣 We are thrilled to announce that on AUGUST 24th at 7 pm eastern we are hosting a webinar to provide the community with information about the recent PIONEER trial of Avapritinib. You can save your seat for the webinar by registering here: buff.ly/4441sW7